Testing three drugs together versus one drug for advanced colorectal cancer

This trial is testing whether a combination of three medications—tucidinostat, sintilimab, and bevacizumab—works better than a single medication called fruquintinib for people with advanced colorectal cancer that has progressed despite earlier treatments. About 430 people will be randomly assigned to receive either the three-drug combination or the single medication. The goal is to see which approach helps people live longer and controls their cancer better.

Many people with advanced colorectal cancer stop responding to standard treatments, and there are limited options left. Researchers believe that combining three different types of medications—each working in different ways to fight cancer—might be more effective than using a single drug alone.